证券代码：300677 证券简称：英科医疗 公告编号：2025-135 英科医疗科技股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 具体内容请详见同日登载于巨潮资讯网（www.cninfo.com.cn）上 的《关于调整 2025 年限制性股票激励计划相关事项的公告》（公告 编号：2025-136） 本议案已经公司第四届董事会薪酬与考核委员会第五次会议审 议通过。 表决结果：同意6票、反对0票、弃权0票。公司董事陈琼、于海 生、朱丽丽回避表决。 2、审议通过《关于向激励对象授予2025年限制性股票激励计划 预留股份的议案》 一、董事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第四届董事会 第十次会议于 2025 年 10 月 15 日在公司会议室以现场结合通讯方式 召开，会议通知已于 2025 年 10 月 13 日以专人送达、电子邮件、传 真或即时通讯工具等形式向全体董事发出。会议由公司董事长刘方毅 先生召集和主持，本次会议应出席董事 9 名，实际出席会议董事 9 名， 公司高级管理人员列席了本次会议。 ...

Market Overview - The medical device sector experienced a decline of 0.96% on October 14, with Hualan Co. leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Top Performers - Yingke Medical (300677) saw a significant increase of 12.69%, closing at 43.52 with a trading volume of 463,500 shares and a turnover of 1.963 billion [1] - Zhend Medical (603301) rose by 9.02%, closing at 65.89 with a trading volume of 151,400 shares and a turnover of 980 million [1] - Other notable gainers include JinHao Medical (920925) up 5.80%, Jiuan Medical (002432) up 4.06%, and Canar Co. (301122) up 3.47% [1] Underperformers - Hualan Co. (301093) fell by 6.45%, closing at 37.26 with a trading volume of 40,800 shares and a turnover of 157 million [2] - Aohua Endoscopy (688212) decreased by 5.64%, closing at 48.20 with a trading volume of 32,100 shares and a turnover of 159 million [2] - Other significant declines include Maike Aodi (300341) down 4.00% and Huachuang Technology (688151) down 3.57% [2] Capital Flow - The medical device sector saw a net outflow of 173 million from institutional investors, while retail investors experienced a net inflow of 69.34 million [2] - The sector's capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 23.6 million from institutional investors, but a net outflow of 21.46 million from retail investors [3] - Yingke Medical (300677) experienced a net inflow of 96.89 million from institutional investors, with retail investors seeing a net outflow of 61.25 million [3] - Jiuan Medical (002432) had a net inflow of 39.29 million from institutional investors, while retail investors had a net inflow of 16.09 million [3]

Core Viewpoint - The trading volume of Yingke Medical reached 1.654 billion yuan, marking a new high since October 9, 2024, with the stock price increasing by 13.90% and a turnover rate of 8.44% [2] Summary by Category - **Trading Performance** - The latest trading volume for Yingke Medical was 1.654 billion yuan, which is the highest since October 9, 2024 [2] - The stock price rose by 13.90% during this trading session [2] - The turnover rate for the stock was recorded at 8.44% [2] - The previous trading day's total volume was 832 million yuan [2]

证券代码：300677 证券简称：英科医疗 公告编号：2025-134 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担 ...

Core Insights - The rehabilitation equipment industry in China is rapidly growing, with the market size expected to reach approximately 714.6 billion yuan in 2024, an increase of 98.9 billion yuan from 2023 [1][6] - The largest market share within the rehabilitation equipment sector is held by rehabilitation therapy devices at 15%, followed by rehabilitation training devices at 4%, and rehabilitation assessment devices at 1% [6] - The market is projected to grow further, reaching an estimated 815 billion yuan by 2025, driven by an aging population and increasing demand for rehabilitation services [1][6] Industry Definition and Classification - Rehabilitation medical devices are defined as equipment used for the prevention, assessment, treatment, training, or compensation of functional disabilities [3] - The main categories of rehabilitation medical devices include rehabilitation aids, rehabilitation therapy devices, rehabilitation training devices, rehabilitation assessment devices, and other rehabilitation equipment [3] Current Development Status - The rehabilitation equipment market in China is predominantly composed of domestic brands, which account for 97.9% of the market, while imported brands make up about 3% [6] - The industry has seen significant expansion in both market size and application areas due to rapid economic development [6] Industry Chain - The upstream of the rehabilitation equipment industry includes raw materials and software systems, while the midstream involves the manufacturing of rehabilitation devices [8] - The downstream applications primarily serve hospitals, community rehabilitation centers, nursing homes, and other medical institutions catering to populations with functional disabilities [8] Market Environment and Policies - The Chinese government has shown strong support for the rehabilitation equipment industry through various policies aimed at promoting its development, such as the "14th Five-Year" National Health Plan and guidelines for enhancing the welfare of the elderly [11] Competitive Landscape - Major companies in the rehabilitation medical device sector include Yuyue Medical, Kefu Medical, and Xiangyu Medical, with Yuyue Medical leading the market in terms of capital and revenue [12] - The industry exhibits a tiered competitive structure, with leading companies in the first tier and several others in subsequent tiers [12] Future Trends - The rehabilitation equipment industry is expected to experience significant growth opportunities, particularly in home settings, driven by an aging population and increasing chronic disease prevalence [13] - The industry is anticipated to evolve towards high-quality development, supported by technological advancements and favorable government policies [13]

Group 1 - The core point of the news is that Yingke Medical's stock price increased by 5.23% to 38.62 CNY per share, with a trading volume of 391 million CNY and a turnover rate of 2.25%, resulting in a total market capitalization of 25.288 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - Dachen Fund has a significant holding in Yingke Medical, with its Dachen Growth Mixed Fund (160926) increasing its stake by 120,000 shares in the second quarter, bringing the total to 848,900 shares, which accounts for 3.37% of the fund's net value [2] - The Dachen Growth Mixed Fund has a current size of 449 million CNY and has achieved a year-to-date return of 26.47%, ranking 4062 out of 8166 in its category [2] Group 3 - The fund manager of Dachen Growth Mixed Fund is Zou Jian, who has been in the position for 4 years and 259 days, managing a total asset size of 1.086 billion CNY [3] - During Zou Jian's tenure, the best fund return was 12.49%, while the worst return was -21.29% [3]

Market Overview - On September 26, the medical device sector declined by 1.68%, with JinHao Medical leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the medical device sector included: - Xiangsheng Medical (688358) with a closing price of 32.90, up 9.30% [1] - ST Kelly (300326) with a closing price of 5.88, up 3.70% [1] - Shengxiang Biology (688289) with a closing price of 20.50, up 3.07% [1] - Conversely, JinHao Medical (872925) saw a significant decline of 11.00%, closing at 33.00 [2] - Other notable decliners included: - JiMin Health (603222) down 8.46% to 10.71 [2] - Sino Medical (688108) down 5.18% to 26.55 [2] Trading Volume and Capital Flow - The medical device sector experienced a net outflow of 621 million yuan from institutional investors, while retail investors saw a net inflow of 489 million yuan [2] - The trading volume for Xiangsheng Medical was 55,000 shares, with a transaction value of 177 million yuan [1] - The trading volume for ST Kelly was 182,000 shares, with a transaction value of 106 million yuan [1] Capital Inflow Analysis - Major stocks with net inflows from institutional investors included: - Yingke Medical (300677) with a net inflow of 87.8 million yuan [3] - Shengxiang Biology (688289) with a net inflow of 41.2 million yuan [3] - Stocks with significant net outflows from retail investors included: - Yingke Medical with a net outflow of 84.4 million yuan [3] - Shengxiang Biology with a net outflow of 21.8 million yuan [3]

9月26日，英科医疗涨5.33%，截至发稿，报38.76元/股，成交4.43亿元，换手率2.54%，总市值253.80亿 元。 刘树荣累计任职时间8年73天，现任基金资产总规模1122.99亿元，任职期间最佳基金回报194.12%， 任 职期间最差基金回报-48.01%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 易方达创业板ETF（159915）成立日期2011年9月20日，最新规模855.37亿。今年以来收益52.86%，同 类排名567/4220；近一年收益99.22%，同类排名530/3824；成立以来收益267.89%。 易方达创业板ETF（159915）基金经理为成曦、刘树荣。 截至发稿，成曦累计任职时间9年145天，现任基金资产总规模1953.12亿元，任职期间最佳基金回报 131.04%， 任职期间最差基金回报-67.89%。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东 ...

Core Viewpoint - In recent trading, Yingke Medical's stock price has shown significant growth, with a year-to-date increase of 49.08% and a market capitalization of 24.581 billion yuan [1] Group 1: Stock Performance - As of September 26, Yingke Medical's stock price rose by 2.01% to 37.54 yuan per share, with a trading volume of 171 million yuan and a turnover rate of 1.00% [1] - The stock has experienced a 5-day increase of 5.27%, a 20-day increase of 2.21%, and a 60-day increase of 46.64% [1] Group 2: Financial Performance - For the first half of 2025, Yingke Medical reported a revenue of 4.913 billion yuan, representing a year-on-year growth of 8.90%, and a net profit attributable to shareholders of 710 million yuan, up 21.02% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Yingke Medical was 60,000, a decrease of 2.96% from the previous period, with an average of 7,825 circulating shares per person, an increase of 3.07% [2] - The company has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed in the last three years [3] Group 4: Institutional Holdings - As of June 30, 2025, the second-largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 15.0151 million shares, an increase of 291,500 shares from the previous period [3] - Other notable institutional shareholders include E Fund Growth ETF and Southern CSI 500 ETF, with varying changes in their holdings [3]

Company Overview - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009. The company was listed on July 21, 2017. Its main business includes three segments: personal protection (91.47%), rehabilitation care (4.75%), and other products (3.77%) [1][2]. Financial Performance - As of June 30, 2025, Yingke Medical achieved a revenue of 4.913 billion yuan, representing a year-on-year growth of 8.90%. The net profit attributable to shareholders was 710 million yuan, reflecting a year-on-year increase of 21.02% [2]. - The company has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yingke Medical's stock price decreased by 2.01%, closing at 37.00 yuan per share, with a trading volume of 468 million yuan and a turnover rate of 2.67%. The total market capitalization is 24.227 billion yuan [1]. - Year-to-date, the stock price has increased by 46.94%, with a 3.99% rise over the last five trading days, a 1.73% decline over the last 20 days, and a 45.15% increase over the last 60 days [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders is 60,000, a decrease of 2.96% from the previous period. The average number of circulating shares per person is 7,825, an increase of 3.07% [2][3]. - The top circulating shareholders include Huabao Zhongzheng Medical ETF, E Fund Growth ETF, and Southern CSI 500 ETF, with varying changes in their holdings [3].